Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Association of BRAF Mutation Status with Histopathological Characteristics and Survival Outcomes in Stage II-III Malignant Melanoma.

International journal of molecular sciences - 9 Jul 2026

Gâta Vlad Alexandru, Leucuța Daniel Corneliu, Ilieș Radu Alexandru, Țîțu Ștefan, Mureșan-Bădescu Ana Maria, Nicoară Delia, Pop Ioan Constantin, Orădan Alex Victor, Muntean Maximilian Vlad, Gâta Anda

Abstract excerpt

In patients with advanced or metastatic melanoma, BRAF mutation assessment is routinely performed to identify patients who may benefit from BRAF-targeted therapy. This study aimed to assess the role of BRAF mutation status in relation to histopathological characteristics and survival of patients with stage II and III malignant melanoma. A prospective cohort of 108 patients with pT3 malignant melanoma who were...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Lymphocytes, Tumor-Infiltrating

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Melanoma

Share to Mutation

Share to Neoplasm Staging

Share to Prognosis

Share to Proto-Oncogene Proteins B-raf

Share to Skin Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 42511497
DOI: 10.3390/ijms27146150
PMCID: PMC13410214

Genes

BRAF

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Association of BRAF Mutation Status with Histopathological Characteristics and Survival Outcomes in Stage II-III Malignant Melanoma.PMID 42511497Read ↗

The Impact of BRAF Mutational Status on Survival in Melanoma Patients: Single Centre Experience.Semantic proximity Read ↗

From Breslow to BRAF and immunotherapy: evolving concepts in melanoma pathogenesis and disease progression and their implications for changing management over the last 50 years.Semantic proximity Read ↗

Clinical characteristics and treatment outcomes of non-V600 E/K BRAF mutant melanoma patients: a single-institution experience.Semantic proximity Read ↗

Comparative analysis of adjuvant therapy for stage III BRAF-mut melanoma: A real-world retrospective study from single center in China.Semantic proximity Read ↗

Assessing melanoma prognosis: the interplay between patient profiles, survival, and BRAF, NRAS, KIT, and TWT mutations in a retrospective multi-study analysis.Semantic proximity Read ↗

A national cohort study of melanoma BRAF status, testing patterns, patient and tumour characteristics, treatment and survival in England from 2016 to 2021.Semantic proximity Read ↗

European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment - Update 2022.Semantic proximity Read ↗

Melanoma: diagnosis, staging, and treatment. Consensus group recommendations.Semantic proximity Read ↗

Frontline approach to metastatic BRAF-mutant melanoma diagnosis, molecular evaluation, and treatment choice.Semantic proximity Read ↗

Clinicopathological features and clinical outcomes associated with TP53 and BRAFNon-V600 mutations in cutaneous melanoma patients.Semantic proximity Read ↗

Primary Melanoma Histologic Subtype: Impact on Survival and Response to Therapy.Semantic proximity Read ↗

Prognostic value of BRAF(V⁶⁰⁰) mutations in melanoma patients after resection of metastatic lymph nodes.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.